Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01793051 · ClinicalTrials.gov registry record · Phase 2
Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT01793051: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01793051 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01793051, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if minocycline can help reduce the symptoms reported by patients with MM who receive therapy with lenalidomide. Minocycline is an antibiotic and has been shown to interrupt pro-inflammatory cytokine production, which may help to reduce multiple symptoms.
Interventions
- OTHER Placebo
- BEHAVIORAL Questionnaires
- DRUG Minocycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2013-03-22 |
| Est. Completion | 2020-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01793051
The ClinicalTrials.gov registry entry for NCT01793051 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01793051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01793051 about?
NCT01793051 is a clinical study titled "Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma". The goal of this clinical research study is to learn if minocycline can help reduce the symptoms reported by patients with MM who receive therapy with lenalidomide. Minocycline is an antibiotic and has been shown to interrupt pro-inflammatory cytokine production, which may help to reduce multiple s...
What is the current status of trial NCT01793051?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2013-03-22. Estimated completion is 2020-09-18.
What interventions are being tested in trial NCT01793051?
The interventions under investigation include: Placebo (OTHER), Questionnaires (BEHAVIORAL), Minocycline (DRUG).
Who is sponsoring clinical trial NCT01793051?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.